信邦制药(002390) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥1,460,050,741.08, representing a 17.21% increase compared to ¥1,245,619,839.85 in the same period last year[9]. - Net profit attributable to shareholders was ¥72,181,104.84, a significant increase of 654.54% from a loss of ¥13,016,487.45 in the previous year[9]. - The net profit after deducting non-recurring gains and losses was ¥68,549,603.42, up 636.75% from a loss of ¥12,771,310.23 in the same period last year[9]. - Basic earnings per share rose to ¥0.05, compared to a loss of ¥0.01 per share in the same period last year, marking a 600.00% increase[9]. - Net profit for the quarter was ¥78,027,582.13, a significant recovery from a net loss of ¥40,370,553.85 in the same period last year[67]. - The net profit attributable to shareholders for the first half of 2021 is projected to be between 13,942,000 and 15,730,000 CNY, representing a significant increase of approximately 290.00% compared to the same period last year, which was 3,574,860 CNY[36]. - Basic earnings per share are expected to rise to between 0.08 and 0.09 CNY, reflecting a growth of 300.00% from 0.02 CNY in the previous year[36]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 70.79% to ¥63,718,809.56 from ¥218,161,795.95 in the previous year[9]. - Net cash flow from operating activities decreased by 70.79% to ¥63,718,809.56, due to reduced loan interest subsidies and increased procurement expenses[21]. - The cash flow from operating activities for the current period is CNY 63,718,809.56, a decrease from CNY 218,161,795.95 in the previous period[82]. - The net cash flow from operating activities was 7,070,183.38 CNY, a decrease of 90.4% compared to the previous period's 73,763,994.08 CNY[87]. - The total cash inflow from operating activities is CNY 1,572,629,616.06, slightly down from CNY 1,584,268,793.43 in the previous period[82]. - The company reported a total cash inflow of 117,701,792.20 CNY from operating activities, down from 173,462,097.02 CNY in the prior period[87]. - The ending balance of cash and cash equivalents was 1,264,722,135.94 CNY, compared to 1,060,989,427.82 CNY at the end of the previous period[89]. Assets and Liabilities - Total assets at the end of the reporting period were ¥9,657,719,562.54, a slight decrease of 0.05% from ¥9,662,173,468.05 at the end of the previous year[9]. - The total current assets amounted to CNY 6,111,348,387.77, an increase from CNY 6,091,144,713.82 in the previous period[45]. - The total non-current assets were CNY 3,546,371,174.77, down from CNY 3,571,028,754.23, representing a decrease of approximately 0.7%[48]. - Total liabilities amounted to CNY 4,411,188,801.87, a decrease from CNY 4,493,670,289.51, indicating a reduction of about 1.8%[51]. - Total liabilities rose to ¥2,297,546,976.73, up from ¥2,176,765,333.81, indicating an increase of 5.5%[61]. - The total equity attributable to shareholders was CNY 4,990,521,030.57, an increase from CNY 4,918,339,925.73, reflecting a growth of approximately 1.5%[54]. Research and Development - R&D expenses dropped by 94.51% to ¥439,885.17 compared to the same period last year, primarily due to the sale of subsidiaries[21]. - Research and development expenses were significantly reduced to ¥439,885.17 from ¥8,013,263.91, a decrease of 94.5%[64]. - Research and development expenses for the current period are CNY 50,420.59, up from CNY 35,841.12 in the previous period[71]. Financing Activities - Net cash flow from financing activities fell by 81.48% to ¥43,851,023.26, as there were no stock buybacks this period and bank loan repayments increased[21]. - Cash inflow from financing activities was 445,000,000.00 CNY, an increase from 301,236,766.01 CNY in the prior period[89]. - The net cash flow from financing activities was 146,582,287.00 CNY, up from 123,256,273.13 CNY in the previous period[89]. - The company plans to use proceeds from a non-public stock issuance of 36 million shares at ¥4.20 per share to supplement working capital and repay bank loans[24]. Government Support and Subsidies - The company reported government subsidies recognized in the current period amounting to ¥5,504,105.94[9]. - Other income rose by 302.34% to ¥5,504,105.94, driven by increased government subsidies[21]. Future Outlook and Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[76]. - The impact of COVID-19 on the company's operations has been significant in the first quarter, but recovery is expected in the second quarter[36]. - The company is actively working on asset integration plans to avoid competition between Yuheng Pharmaceutical and Xinpang Pharmaceutical after the share transfer is completed[31].